Novavax Stock Today

NVAX Stock  USD 4.85  0.14  2.97%   

Performance

2 of 100

 
Low
 
High
Weak

Odds Of Distress

Over 60

 
100  
 
Zero
Above Average
Novavax is trading at 4.85 as of the 28th of March 2024; that is 2.97% increase since the beginning of the trading day. The stock's open price was 4.71. Novavax has more than 60 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Novavax are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
5th of December 1995
Category
Healthcare
Classification
Health Care
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. The company has 139.95 M outstanding shares of which 48.13 M shares are now shorted by private and institutional investors with about 4.83 trading days to cover. More on Novavax

Moving together with Novavax Stock

  0.66MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr

Moving against Novavax Stock

  0.63VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
  0.62TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr

Novavax Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novavax's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novavax or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEOStanley Erck
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Novavax report their recommendations after researching Novavax's financial statements, talking to executives and customers, or listening in on Novavax's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Novavax. The Novavax consensus assessment is calculated by taking the average forecast from all of the analysts covering Novavax.
Financial Strength
Based on the key measurements obtained from Novavax's financial statements, Novavax may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Novavax is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.560.5302
Notably Up
Slightly volatile
Total Current Liabilities1.7 B1.6 B
Sufficiently Up
Slightly volatile
Total Assets1.9 B1.9 B
Sufficiently Up
Slightly volatile
Total Current Assets1.2 B1.1 B
Sufficiently Up
Slightly volatile
Novavax's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Novavax's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Novavax's financial leverage. It provides some insight into what part of Novavax's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Novavax's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Novavax deploys its capital and how much of that capital is borrowed.
Liquidity
Novavax cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 280.63 M in liabilities with Debt to Equity (D/E) ratio of 8.24, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novavax has a current ratio of 1.03, suggesting that it may not be capable to disburse its financial obligations when due. Debt can assist Novavax until it has trouble settling it off, either with new capital or with free cash flow. So, Novavax's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novavax sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novavax to invest in growth at high rates of return. When we think about Novavax's use of debt, we should always consider it together with cash and equity.

Total Cash From Financing Activities

7.65 Million
Novavax (NVAX) is traded on NASDAQ Exchange in USA. It is located in 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878 and employs 1,543 people. Novavax is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 659.18 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novavax's market, we take the total number of its shares issued and multiply it by Novavax's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novavax conducts business under Biotechnology sector and is part of Health Care industry. The entity has 139.95 M outstanding shares of which 48.13 M shares are now shorted by private and institutional investors with about 4.83 trading days to cover. Novavax currently holds about 1.28 B in cash with (717.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Novavax Probability Of Bankruptcy
Ownership Allocation
Novavax maintains a total of 139.95 Million outstanding shares. Over half of Novavax's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Novavax. Please watch out for any change in the institutional holdings of Novavax as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novavax Ownership Details

Novavax Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Novavax jumping above the current price in 90 days from now is about 37.39%. The Novavax probability density function shows the probability of Novavax stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Novavax has a beta of -0.8884. This indicates Additionally, novavax has an alpha of 0.2177, implying that it can generate a 0.22 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 4.85HorizonTargetOdds Above 4.85
62.48%90 days
 4.85 
37.39%
Based on a normal probability distribution, the odds of Novavax to move above the current price in 90 days from now is about 37.39 (This Novavax probability density function shows the probability of Novavax Stock to fall within a particular range of prices over 90 days) .

Novavax Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Novavax that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Novavax's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Novavax's value.
InstituionRecorded OnShares
Rafferty Asset Management, Llc2023-09-30
992.5 K
Tsp Capital Management Group/llc2023-09-30
966.4 K
Northern Trust Corp2023-09-30
865.8 K
Charles Schwab Investment Management Inc2023-09-30
703.4 K
Rock Springs Capital Management Lp2023-09-30
647.7 K
Bnp Paribas Arbitrage, Sa2023-09-30
583.1 K
Goldman Sachs Group Inc2023-09-30
565.8 K
Barclays Plc2023-09-30
553.8 K
Allianz Asset Management Ag2023-09-30
434.9 K
Vanguard Group Inc2023-09-30
11.6 M
State Street Corporation2023-09-30
10.2 M
View Novavax Diagnostics

Novavax Historical Income Statement

Novavax Income Statement is one of the three primary financial statements used for reporting Novavax's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Novavax revenue and expense. Novavax Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Novavax's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 15.1 M in 2024, despite the fact that Operating Income is likely to grow to (394.3 M). View More Fundamentals

Novavax Stock Against Markets

Picking the right benchmark for Novavax stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Novavax stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Novavax is critical whether you are bullish or bearish towards Novavax at a given time. Please also check how Novavax's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Novavax without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sign In To Macroaxis Now

   

Sign In To Macroaxis

Sign in to explore Macroaxis' wealth optimization platform and fintech modules
All  Next Launch Module

Novavax Corporate Directors

Novavax corporate directors refer to members of a Novavax board of directors. The board of directors generally takes responsibility for the Novavax's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Novavax's board members must vote for the resolution. The Novavax board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Michael McManusIndependent DirectorProfile
Rachel KingDirectorProfile
Gary EvansIndependent DirectorProfile
Rajiv ModiDirectorProfile

How to buy Novavax Stock?

Before investing in Novavax, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Novavax. To buy Novavax stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Novavax. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Novavax stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Novavax stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Novavax stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Novavax, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Already Invested in Novavax?

The danger of trading Novavax is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Novavax is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Novavax. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Novavax is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.
Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Novavax Stock analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Share Portfolio
Track or share privately all of your investments from the convenience of any device
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.41)
Revenue Per Share
9.762
Quarterly Revenue Growth
(0.18)
Return On Assets
(0.17)
Return On Equity
(8.98)
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.